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Abstract
 
Only a few autoantibodies that are more or less specific for
RA have been described so far. The rheumatoid factor most
often tested for is not very specific for RA, while the more
specific antiperinuclear factor for several reasons is not rou-
tinely used as a serological parameter. Here we show that
autoantibodies reactive with synthetic peptides containing
the unusual amino acid citrulline, a posttranslationally modi-
fied arginine residue, are specifically present in the sera of
RA patients. Using several citrulline-containing peptide vari-
ants in ELISA, antibodies could be detected in 76% of RA
sera with a specificity of 96%. Sera showed a remarkable va-
riety in the reactivity pattern towards different citrulline-
containing peptides. Affinity-purified antibodies were shown
to be positive in the immunofluorescence-based antiperinu-
clear factor test, and in the so-called antikeratin antibody
test, and were reactive towards filaggrin extracted from hu-
man epidermis. The specific nature of these antibodies and
the presence of these antibodies early in disease, even before
other disease manifestations occur, are indicative for a pos-
sible role of citrulline-containing epitopes in the pathogene-
sis of RA. (
 
J. Clin. Invest.
 
 1998. 101:273–281.) Key words:
antiperinuclear factor 
 
•
 
 antikeratin antibodies 
 
•
 
 rheumatoid
factor 
 
•
 
 autoantigen 
 
•
 
 autoimmunity 
 
•
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Introduction
 
RA is a systemic autoimmune disease of unknown etiology.
The disease is characterized by chronic inflammation of the
joints eventually resulting in tissue degradation and joint de-
formation that can lead to severe disability. RA is the most
common of the inflammatory joint diseases, affecting 1–2% of
the world population.
The diagnosis of RA depends primarily on clinical manifes-
tations of the disease, with only limited serological support.
The only serological test routinely used is to determine the
presence of rheumatoid factors (RF)
 
1
 
 in the serum. RF are an-
tibodies directed to the constant region of immunoglobulins of
the IgG subclass, and their presence is determined by aggluti-
nation assays, nephelometry, or ELISA-based tests. RF can be
detected in up to 70–80% of RA patients, but is also detected
in relatively high percentages in other autoimmune and infec-
tious diseases, and in up to 15% of healthy individuals (1).
Antibodies of a more specific nature have also been found
in sera of RA patients. Such antibodies were first described by
Nienhuis en Mandema (2), who discovered that antibodies in
RA sera specifically label the perinuclear factor, a component
of a number of so-called keratohyaline granules surrounding
the nucleus in indirect immunofluorescence (IIF) using buccal
mucosa (BM) cells. These antiperinuclear factor (APF) anti-
bodies are reported to be present in 49–91% of RA patients
with a specificity between 73 and 99% (3). Not all BM cells do-
nated are suited as an antigenic substrate. A high percentage
of APF-positive BM cells can only be found in 
 
z 
 
5% of the do-
nors. This dependence on availability of suitable donors and
the inconvenience of the IIF test format are the main reasons
why the APF test is not routinely used. 
A third class of antibodies specifically present in RA sera
are the so-called antikeratine antibodies (AKA). Their pres-
ence is determined by IIF on cryosections of rat esophagus.
AKA label the cells of the stratum corneum of rat esophagus
epithelium (4). The sensitivity of the AKA test reported varies
between 36 and 59%, with a specificity between 88 and 99%
(3). Again, the presence of AKA is not routinely tested for be-
cause of the inconvenient antigenic substrate and the use of
IIF that is regarded as a problem in a routine laboratory set-
ting.
The nature of the antigen recognized by both the AKA and
APF antibodies has until recently been unclear. It was shown
that the APF and a monoclonal antibody specific for human
(pro)filaggrin produce an identical staining pattern in IIF (5).
A 40-kD protein extracted from human epidermis, specifically
labeled by RA sera in Western blots, was identified as a neu-
tral/acidic isoform of filaggrin (6). Moreover, it was demon-
strated that the IgG fraction, affinity-purified from patient
sera by using the 40-kD protein, was reactive in both the APF
and AKA test, indicating that the AKA and APF antibodies
are at least partly the same (7). The immunological relation-
ship between APF and AKA had already been proposed
based on the strong correlation of the presence of APF and
AKA in patient sera (3). The high specificity of the APF/AKA
antibodies and their presence early in disease, often before
apparent disease manifestations are noted (8, 9), are indicative
for a possible role of these antibodies in the pathogenesis of RA.
Filaggrin (filament-aggregating protein) is produced during
the late stages of terminal differentiation of epithelial cells in
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mammals. It is synthesized as a heavily phosphorylated precur-
sor protein (profilaggrin) that consists of 10–12 filaggrin re-
peats (10). Profilaggrin is deposited in granules, and filaggrin is
released by proteolytic cleavage during differentiation of the
cells. During this stage the protein is dephosphorylated, and
 
z 
 
20% of the arginine residues are converted into citrulline by
the enzyme peptidylarginine deiminase. The large heterogene-
ity in amino acid sequence of filaggrin (30–40% of the amino
acid residues of the filaggrin repeat units are variable) and the
partial citrullination of arginine residues result in an extensive
charge heterogeneity (11).
Although the antigen recognized by the APF antibodies in
IIF of BM cells has been identified as filaggrin, it remains un-
clear from where these antibodies present in RA sera origi-
nate. Based on the observation that the AKA/APF antibodies
are reactive with the acidic/neutral isoform of filaggrin (6), the
possibility that citrulline residues might be present in the
epitopes was investigated. To study this possibility, several
peptides were synthesized in which arginine residues encoun-
tered in the cDNA-derived profilaggrin sequence were substi-
tuted with citrulline. The prevalence of antibodies against these
peptides in RA sera and their relation with the APF/AKA an-
tibodies are investigated in this study. Furthermore, possible
mechanisms for the specific occurrence of these antibodies in
RA sera are discussed.
 
Methods
 
Sera and IgG purification. 
 
Sera were collected from the outpatients
clinic of the Department of Rheumatology of the University Hospital
Nijmegen. During a 3-wk period, a total of 288 sera were collected
from patients, of which 134 were diagnosed as RA according to the
revised criteria formulated by the American Rheumatology Associa-
tion (ARA; 12). The remaining 154 sera, hereafter referred to as con-
trol sera, were taken from patients with various rheumatic complaints
(23 ankylosing spondylitis, 15 systemic sclerosis, 11 psoriatic arthritis,
8 SLE, 7 undifferentiated connective tissue disease, 7 polyarticular
arthrosis, 5 juvenile chronic arthritis, 5 polymyalgia rheumatica, 4
mixed connective tissue disease, 4 polymyositis, and 65 miscellaneous
rheumatic complaints). Sera were stored at 
 
2
 
80
 
8
 
C until use, and were
tested for autoantibody activity without prior knowledge of the diag-
nosis. In addition, 200 sera (50 SLE, 50 systemic sclerosis, 50 dermato-
myositis/polymyositis, and 50 primary Sjögren’s syndrome) were used
to further assess specificity. IgG was purified chromatographically
from patient sera using protein A–Sepharose (Pharmacia Fine Chem-
icals, Uppsala, Sweden) by standard procedures (13). 
 
Peptide synthesis. 
 
Peptides were selected for synthesis from
amino acid sequences deduced from known cDNA sequences of hu-
man profilaggrin (10, 11). All complete human filaggrin sequences
found in the SwissProt and EMBL databases were used for a com-
puter analysis of probable antigenic sites. Regions with a high antige-
nicity index according to Jameson and Wolf (14) and a high probability
of containing turns according to secondary structure predictions (15)
were identified. Peptides were synthesized by the solid-phase strategy
using fmoc chemistry as described previously (16). The peptides were
at least 90% pure as deduced from their elution pattern on reversed-
phase HPLC and the relative absorption at 214 nm. The identity of
the peptides was confirmed by mass spectrometry (matrix-assisted laser
desorption/ionization mass spectrometry). Key peptides in this study
(cfc1 and cf0; Table I) were resynthesized on a larger scale and puri-
fied using preparative reversed-phase HPLC. Purity of these peptides
was at least 98%. All peptides were synthesized as peptide amides.
Peptides used in this study are listed in Table I.
 
Immunoblot on epidermal filaggrin. 
 
Filaggrin was extracted from
human epidermis as described previously (6) and after SDS-PAGE
was electroblotted to nitrocellulose (0.5 
 
m
 
g/strip). Blot strips were
blocked with 0.5% skimmed milk powder in TBST (50 mM Tris-HCl,
pH 7.4; 150 mM NaCl 0.05% Tween-20) and incubated with sera di-
luted 1:50 in the same buffer for 2 h. After washing, the strips were in-
cubated with anti–human IgG conjugated to alkaline phosphatase
(D0336, Dako SA, Glostrup, Denmark) diluted 1:1000 for 1 h. For
detection, the strips were developed using NBT/BCIP (Research Or-
ganics, Cleveland, OH; 13). 
 
Indirect immunofluorescence.
 
Detection of APF antibodies by
IIF on buccal mucosa cells was performed as described (5). The se-
rum dilution used was 1:10. Buccal mucosa cells from a single donor
were used throughout this study. Detection of AKA antibodies was
performed on cryosections of rat esophagus prepared as described
previously (17).
 
Peptide ELISA. 
 
Peptides were coupled covalently to 96-well as-
say plates (Costar Corp., Cambridge, MA) at 1 
 
m
 
g/well. Coupling was
performed at 4
 
8
 
C for 16 h at pH 9.0. For blank controls, wells were
coupled with 2 
 
m
 
g BSA/well. All wells were blocked with 2% BSA for
1 h. Sera were diluted 200-fold in RIA (1% BSA, 350 mM NaCl, 10 mM
Tris-HCl, pH 7.6, 1% [vol/vol] Triton X-100, 0.5% [wt/vol] Na-deoxy-
cholate, 0.1% SDS) supplemented with 10% normal rabbit serum,
and incubated for 1.5 h at room temperature. After washing (6 times
with PBS/0.05% [vol/vol] Tween-20), 100 
 
m
 
l of anti–human IgG con-
jugated to peroxidase (P0214, Dako SA) diluted 1:1,000 in RIA was
 
Table I. Sequence of Synthetic Peptides
 
Peptide name Sequence*
Corresponding filaggrin
region and substitutions
 
cf0
 
SHQESTRGRSRGRSGRSGS
 
306-324
cfA
 
SHQESTAGRSRGRSGRSGS
 
306-324 Arg
 
312
 
fi
 
Ala
cfE
 
SHQESTEGRSRGRSGRSGS
 
306-324 Arg
 
312
 
fi
 
Glu
cfQ
 
SHQESTQGRSRGRSGRSGS
 
306-324 Arg
 
312
 
fi
 
Gln
cfZ
 
SHQESTZGRSRGRSGRSGS
 
306-324 Arg
 
312
 
fi
 
Orn
cfc1
 
SHQESTXGRSRGRSGRSGS
 
306-324 Arg
 
312
 
fi
 
Cit
cfc2
 
SHQESTRGXSRGRSGRSGS
 
306-324 Arg
 
314
 
fi
 
Cit
cfc3
 
SHQESTRGRSXGRSGRSGS
 
306-324 Arg
 
316
 
fi
 
Cit
cfc4
 
SHQESTRGRSRGXSGRSGS
 
306-324 Arg
 
318
 
fi
 
Cit
cfc5
 
SHQESTRGRSRGRSGXSGS
 
306-324 Arg
 
321
 
fi
 
Cit
cfc6
 
SHQESTXGXSRGRSGRSGS
 
306-324 Arg
 
312 
 
1
 
 314
 
fi
 
Cit
cfc7
 
SHQESTXGRSXGRSGRSGS
 
306-324 Arg
 
312 
 
1
 
 316
 
fi
 
Cit
cfc8
 
SHQESTXGRSRGXSGRSGS
 
306-324 Arg
 
312 
 
1
 
 318
 
fi
 
Cit
cfc9
 
SHQESTXGRSRGRSGXSGS
 
306-324 Arg
 
312 
 
1
 
 321
 
fi
 
Cit
cfc1-319
 
SHQESTXGRSRGRS
 
306-319 Arg
 
312
 
fi
 
Cit
cfc1-318
 
SHQESTXGRSRGR
 
306-318 Arg
 
312
 
fi
 
Cit
cfc1-317
 
SHQESTXGRSRG
 
306-317 Arg
 
312
 
fi
 
Cit
cfc1-316
 
SHQESTXGRSR
 
306-316 Arg
 
312
 
fi
 
Cit
cfc1-315
 
SHQESTXGRS
 
306-315 Arg
 
312
 
fi
 
Cit
cfc1-314
 
SHQESTXGR
 
306-314 Arg
 
312
 
fi
 
Cit
f12-31
 
ESSHGWTGPSTRGRQGSRHE
 
12-31
cf18-31
 
TGPSTRGRQGSXHE
 
18-31 Arg
 
29
 
fi
 
Cit
cf18-34-1
 
TGPSTRGRQGSXHEQAQ
 
18-34 Arg
 
29
 
fi
 
Cit
cf18-34-2
 
TGPSTRGXQGSRHEQAQ
 
18-34 Arg
 
25
 
fi
 
Cit
cf18-34-3
 
TGPSTXGRQGSRHEQAQ
 
18-34 Arg
 
23
 
fi
 
Cit
cf48-65-1
 
TIHAHPGSXRGGRHGYHH
 
48-65 Arg
 
56
 
fi
 
Cit
cf48-65-2
 
TIHAHPGSRXGGRHGYHH
 
48-65 Arg
 
57
 
fi
 
Cit
cf48-65-3
 
TIHAHPGSRRGGXHGYHH
 
48-65 Arg
 
60
 
fi
 
Cit
cf48-65-4
 
TIHAHPGSXXGGRHGYHH
 
48-65 Arg
 
56 
 
1
 
 57
 
fi
 
Cit
cf260-276-1
 
GQASSAXDRGHRGSRGS
 
260-276 Arg
 
266
 
fi
 
Cit
cf260-276-2
 
GQASSARDXGHRGSRGS
 
260-276 Arg
 
268
 
fi
 
Cit
*X, citrulline; Z, ornithine; standard one-letter code is used for the other
amino acid residues.
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added to the wells. After incubation (1 h at room temperature),
plates were washed (6 times PBS/Tween-20), and bound antibodies
were detected with 3,3
 
9
 
-5,5
 
9
 
- tetramethyl-benzidine (Organon-Teknika,
Boxtel, the Netherlands) as a substrate. The reaction (10 min) was
stopped by adding 100 
 
m
 
l 2 M sulfuric acid/well. Plates were read at a
wavelength of 450 nm. All sera were tested in duplicate, and the re-
sults were averaged. Sera resulting in an OD
 
450
 
 of 0.2 after subtrac-
tion of the blank for the particular serum (well lacking peptide), were
considered positive. A control serum was included on all plates to
monitor plate-to-plate variation. Variation never exceeded 5%, and
values were therefore not corrected.
 
Competition assay. 
 
Peptides were coupled to the plates as de-
scribed above. Patient sera were used in a dilution resulting in an
OD
 
450
 
 of 1–2 as determined by an endpoint titration of the serum. A
serial dilution of the competing peptide was added to the serum incu-
bations in the ELISA format described. Noncompeting peptides were
used as a negative control and the same peptide as that coupled to the
plate was used as a positive control. Competition was plotted as per-
centage inhibition against peptide concentration. The OD
 
450
 
 signal of
the blank was defined as 100% inhibition, and the signal without pep-
tide added to serum incubation was defined as 0% inhibition. After
serum/peptide incubation for 2 h, plates were treated as described
above. 
 
Affinity chromatography. 
 
For purification of peptide-binding an-
tibodies from RA sera, an affinity matrix was prepared. Peptide (2 mg)
was coupled to 0.3 g of CH-Sepharose 4B (Pharmacia Fine Chemi-
cals, Uppsala, Sweden) in 0.1 M Na
 
2
 
HCO
 
3
 
/NaH
 
2
 
CO
 
3
 
 (pH 8.0) con-
taining 0.5 M NaCl. The efficiency of coupling was determined by using
a sample of the peptide solution (before coupling) and the superna-
tant after coupling in the competition assay. Coupling efficiencies were
estimated to be at least 90%. Excess reactive groups were blocked by
0.1 M Tris-HCl/0.5 M NaCl. A control column was prepared by block-
ing the reactive groups with Tris/NaCl using the same amount of
resin. Chromatography was carried out at room temperature at a flow
rate of 0.2 ml/min. Protein-A–purified IgG, 20 mg in PBST (PBS/
0.05% Tween-20) obtained from RA sera, was applied to the column
for 2 h. The fraction not bound by the column was saved for analysis.
Hereafter, the column was washed extensively with PBST followed
by the same buffer supplemented with 0.35 M NaCl. During elution
of bound material with 0.1 M glycine-HCl, pH 2.5, fractions of 0.2 ml
were collected and immediately neutralized with 10 ml 2 M Tris (un-
buffered) and subsequently dialyzed against PBS. Alternatively, a
batch-wise procedure was used in which peptide resin was added to
purified IgG and incubated for 2 h. After centrifugation the superna-
tant was saved for analysis, and the resin was washed several times
with PBST. The peptide-bound antibodies were eluted from the resin
with glycine/HCl, neutralized with 2 M Tris, and dialyzed against PBS.
These antibodies were used in blotting procedures and IIF on BM
cells or cryosections of rat esophagus.
Results
Peptide synthesis. Regions within the deduced amino acid se-
quences of human profilaggrins with a high antigenicity index
and a large number of residues with high turn probability were
identified. The most promising were found in the extreme
COOH-terminal regions of the filaggrin subunits (amino acid
residues 306–324). The filaggrin sequence that contained the
largest number of arginine residues within this region, and
therefore the most likely to contain citrulline in the in vivo sit-
uation, was selected for peptide synthesis (cf0; Table I). Sev-
eral peptide variants in which the arginine residues were sub-
stituted with citrulline were synthesized (Table I). Peptides
derived from other regions with high antigenicity index and a
large number of residues with high turn probability (amino
acid residues 18–31, 48–65, and 260–276) in which arginine res-
idues were substituted with citrulline were also synthesized
(Table I). Again, the sequences were based on the filaggrin
subunit that contained the largest number of arginine residues
within the particular region.
Figure 1. Binding of RA antibodies to human filaggrin is inhibited by 
citrullinated peptides. Peptide (10 mg/ml) was added during serum in-
cubation on blotstrips containing filaggrin extracted from human epi-
dermis. A strong reactive serum (a) and a moderately reactive serum 
(b) diluted 50-fold were incubated in the presence of no peptide, lane 
1; cfc1, lane 2; a mixture of the peptides cfc1, cfc2, and cfc3, lane 3; 
cf0, lane 4; cfA, lane 5; cfE, lane 6; cfQ, lane 7; and cfZ, lane 8. Note 
that filaggrin, due to its charge heterogeneity, migrates as a broad 
band in SDS-PAGE. The relative migration of molecular size mark-
ers in kD is indicated at the left.
Figure 2. Antibodies 
purified using a citrulli-
nated peptide coupled 
to an affinity matrix are 
reactive with filaggrin. 
Antibodies were frac-
tionated from an IgG 
preparation derived 
from two different RA 
sera (a and b) by chro-
matography. Antibod-
ies eluted from a col-
umn prepared by 
coupling of peptide 
cfc1 (lane 1), and a con-
trol column (lane 2) 
with no peptide coupled 
were incubated on blot-
strips containing filag-
grin extracted from hu-
man epidermis. As a 
control, blotstrips were 
incubated with the frac-
tions not retained by 
the peptide column 
(lane 3) and the control 
column (lane 4). The relative migration of molecular size markers in 
kD is indicated at the left.
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Figure 3. Antibodies purified from a citrullinated peptide coupled to an affinity matrix are reactive towards the stratum corneum of rat esopha-
gus and keratohyalin granules in BM cells. Cryosections of rat esophagus (A) and unfixed buccal mucosa cells (B) were incubated with (1) an 
AKA and APF-positive serum diluted 1:10, (2) IgG antibodies eluted from a column containing peptide cfc1, and (3) IgG antibodies eluted from 
a control column with no peptide coupled. The nuclei of the buccal mucosa cells were counterstained with ethidium bromide.
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The citrulline-substituted peptide cfc1 is reactive with the
APF/AKA antibodies. Addition of peptide cfc1 (Table I) dur-
ing incubation of RA sera on immunoblots containing human
filaggrin partially inhibited the binding of antibodies to filag-
grin (Fig. 1, strips 2). The peptide containing an unmodified
arginine at the same position (cf0) did not show any inhibition
(Fig. 1, strips 4). Control peptides in which citrulline was sub-
stituted by glutamine (cfE), glutamic acid (cfQ), alanine (cfA),
or ornithine (cfZ; a hydrolysis product of citrulline) did not in-
hibit binding (Fig. 1, strips 5–8), suggesting that not the ab-
sence of arginine, but the presence of citrulline specifically
rendered the peptide autoantigenic. The absence of inhibition
with peptide cfZ shows that citrulline itself, and not a hydroly-
sis product, is responsible for recognition by autoantibodies. A
mixture of equimolar amounts of the citrullinated peptides
cfc1, cfc2, and cfc3 was an even more potent inhibitor of serum
reactivity towards filaggrin (Fig. 1, strip 3). Most RA sera reac-
tive towards filaggrin on blot (about 50% of the sera; data not
shown) were inhibited by the addition of cfc1, but the degree
varied with the serum used independently of the signal
strength of a particular serum on blot.
Antibodies eluted from an affinity column containing cfc1
peptide coupled to the matrix were reactive with filaggrin on
blot. No reactive antibodies could be eluted from a control col-
umn to which no peptide had been coupled (Fig. 2). These af-
finity-purified antibodies also gave the characteristic staining
pattern on rat esophagus cryocoupes (Fig. 3 A) in the AKA-
IIF test, and of the keratohyalin granules in BM cells in the
APF-IIF assay (Fig. 3 B).
To investigate whether the recognition of cfc1 by the au-
toantibodies could be used in a direct binding assay, RA sera
(n 5 134) and control sera (n 5 154) were tested on peptide
cfc1 in ELISA. With a cutoff value of 0.2 (well above the signal
of negative sera 1 3 3 SD), 49 of the RA sera (36%) were re-
active with cfc1, while only one of the control sera (, 1%) was
positive. The control peptides cf0, cfA, cfE, cfQ, and cfZ were
not reactive with RA sera in direct ELISA (data not shown),
and were not able to inhibit antibody binding in an ELISA
competition assay as is illustrated in Fig. 4. 
Reactivity of shortened peptide variants. RA sera (n 5 12)
reactive with cfc1 were assayed in ELISA on shortened vari-
ants of peptide cfc1 (Table I). The peptide missing five COOH-
terminal residues (cfc1–319) was still reactive with the same
number of sera as peptide cfc1, although in most cases the
OD450 value was lower. Surprisingly, the sera showed a distinct
difference in reactivity pattern towards the shortened variants;
for some sera truncation of a peptide by a single residue com-
pletely abrogated reactivity, while for others the reactivity did
not change (Table II). This fact illustrates that even for a rela-
tively small antigenic substrate, there can be large differences
in antibody binding characteristics between individual sera.
Reactivity of variant peptides from the COOH-terminal re-
gion. Peptide variants were synthesized in which other argi-
nine residues within the sequence of cf0 were substituted by
citrulline (cfc2, cfc3, cfc4, and cfc5; Table I) or in which two
arginines were simultaneously substituted by citrulline (cfc6,
cfc7, cfc8, and cfc9; Table I). These peptides were all assayed
in the ELISA test using RA and control sera. Testing of addi-
tional connective tissue disease sera confirms the high specific-
ity of the peptides for antibodies present in RA sera (Table
III). Combining the data presented in Table III, a sensitivity of
Figure 4. Substitution variants of the citrulline-containing peptide 
cfc1 do not compete with anti-cfc1 antibody binding in ELISA. Sub-
stitution variants cfA (Ala), cfE (Glu), cfQ (Gln), cf0 (Arg, the non-
citrullinated peptide) and cfc1 (positive control) were added at differ-
ent concentrations during serum incubation on ELISA with the 
citrulline-containing peptide cfc1 coupled to the plates. Relative inhi-
bition was calculated and plotted as a function of peptide concentra-
tion on a linear scale between 100% inhibition (OD450 of the back-
ground signal with no serum added) and 0% inhibition (OD450 with 
no peptide added).
Table II. Reactivity of RA Sera on Shortened Variants of cfc1
Peptide* No. of positive sera
cfc1 12
cfc1-319 12
cfc1-318 9
cfc1-317 7
cfc1-316 7
cfc1-315 4
cfc1-314 1
*Peptide sequences can be found in Table I.
Table III. Reactivity of Sera with Citrullinated COOH-terminal 
Peptide Variants
Peptide*
RA sera
(%)
(n 5 134)
Control sera
(%)
(n 5 154)
SLE§
(%)
(n 5 50)
SSC§
(%)
(n 5 50)
pSS§
(%)
(n 5 50)
PM/DM§
(%)
(n 5 50)
cfc1 49 (36) 1 (0.6) 1 (2) 0 0 0
cfc2 27 (20) 4 (2.6) 1 (2) 0 1 (2) 1
cfc3 37 (28) 2 (0.6) 0 0 1 (2) 1
cfc4 32 (24) 2 (1.3) 0 0 0 0
cfc5 64 (48) 1 (0.6) 0 1 (2) 2 (4) 1
cfc6 65 (48) 1 (0.6) 0 0 2 (4) 1
cfc7 60 (45) 1 (0.6) 0 0 1 (2) 1
cfc8 55 (41) 1 (0.6) 0 0 1 (2) 1
cfc9 57 (42) 1 (0.6) 0 0 2 (4) 0
cfc1-cfc9‡ 102 (76) 6 (3.9) 2 (4) 1 (2) 3 (6) 1 (2)
APF-IIF 99 (74) 27 (17) — — — —
*Peptide sequences can be found in Table I. ‡Sera positive on at least
one of the peptides. §SSC, systemic sclerosis; pSS, primary Sjögren’s
syndrome; PM/DM, polymyositis/dermatomyositis.
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76% (102/134) with 3.7% (13/354) of false positives (specificity
96%) is obtained.
Striking differences in the reactivity pattern against the
monosubstituted peptides were encountered between individ-
ual sera (Fig. 5). These results suggest that each serum con-
tains a specific subset of antibodies recognizing related citrul-
line-containing epitopes. Moreover, the antibodies differ in
their fine specificity towards the citrulline-containing epitopes,
which is becoming particularly evident in competition assays
using the various peptides (Fig. 6). The results show, for exam-
ple, that for only a certain subset of sera the peptide cfc3 is
able to compete for binding to cfc1.
All double-citrullinated peptide variants (cfc6–cfc9) show
an enhanced sensitivity in ELISA as compared with the mono-
substituted variant cfc1 (Table III). The degree of enhance-
ment is more or less the same for all four peptides, pointing to
a specific conformational effect. Possibly by the introduction
of a second citrulline, and thereby the removal of a positively
charged arginine, the peptide can more easily adopt to a con-
formation that is favorable for antibody binding.
The strong relation between the reactivity towards the cit-
rullinated peptides and the APF-IIF test suggests that these
peptides represent the major epitopes recognized by the APF/
Figure 5. RA sera have different patterns of reactivity with citrulli-
nated peptide variants. The reactivity of 134 RA sera with the citrulli-
nated peptide variants (cfc1–cfc9, see Table I) in ELISA and their 
ability to stain keratohyalin granules in APF-IIF is depicted. High re-
activity (OD450 . 0.5) is depicted as black boxes; lower reactivity 
(OD450 , 0.5 but . 0.2) is depicted as gray boxes. Reactivity below 
the cutoff value (OD , 0.2) is depicted by white boxes. Positive APF-
IIF (right) is depicted by black boxes, weakly positive sera are de-
picted by gray boxes, and a negative result in APF-IIF is depicted by 
white boxes. 
Figure 6. Competition profiles of RA sera. The citrulline substituted 
peptides (cfc2–cfc5), cf0 (Arg, the noncitrullinated peptide) and cfc1 
(positive control) were added at different concentrations during se-
rum (a and b) incubation on ELISA with the citrulline-containing 
peptide cfc1 coupled to the plates. Relative inhibition was calculated 
and plotted as a function of peptide concentration on a linear scale 
between 100% inhibition (OD450 of the background signal with no se-
rum added) and 0% inhibition (OD450 with no peptide added).
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AKA antibodies (Table IV). The distribution of ELISA posi-
tivity over RF-positive (n 5 111) and RF-negative (n 5 23)
sera is given in Table IV. The sensitivity of the ELISA (78%
for RF-positive sera) seems to be somewhat lower (65%) for
RF-negative sera. The number of RF-negative sera is, how-
ever, rather small in the group of sera tested. 
Reactivity of peptides based on other filaggrin regions.
Peptides based on sequences of other regions of the filaggrin
repeats were selected. Criteria for selection were a high inci-
dence of turn probability, a high antigenicity index, and an
arginine pattern that differed to some extent from that of the
cfc peptides (Table I; peptides cf18–31; cf18–34-1 to 3; cf48–
65-1 to 4; cf260–276 1 and 2). To test if these peptides had an
additional value for test performance, the RA sera (n 5 32)
that were negative on cfc1–cfc9 were tested in ELISA for reac-
tivity with these peptides (Table V). Except for peptide cf48–
65-4, on which an additional 8 sera were positive, these pep-
tides had little or no additional value, since sera positive on
cf18–31 (n 5 3), cf18–34-1 (n 5 1), and cf18–34-3 (n 5 2) were
also positive on cf48–65-4. Interestingly, all sera positive on
these peptides were also positive in the APF-IIF test, which
suggests that peptide cf48–65-4 may expose APF/AKA epi-
topes that are not presented by peptides cfc1-cfc9. Taken to-
gether, the additional peptide cf48–65-4 may lift the test sensi-
tivity above the 80% level.
Discussion
In this study we show that citrulline is a major constituent of
antigenic determinants recognized by antibodies present in
RA sera. The observation that a posttranscriptional modifica-
tion of arginine residues creates autoantigenic B cell epitopes
suggests intriguing new possibilities for a mechanism by which
autoantibodies (in this case APF/AKA antibodies) may evolve.
One possibility is that immunological tolerance has been
established for the unmodified protein, but that during some
period of the life span of the protein, arginine is modified to
citrulline. When presented to the immune system, e.g., after
massive cell damage or uncontrolled apoptosis, the modified
antigen could evoke an immune response that, via epitope
spreading, can lead to a polyclonal autoantibody response
against the whole protein or protein-containing complex. It is
likely that such a cascade of immune reactions is restricted to
genetically susceptible individuals. In this way, the introduc-
tion of a modified arginine residue could break tolerance to
this kind of neoepitope as postulated recently for another type
of posttranslational modification (phosphorylation) of autoan-
tigens that occurs during apoptosis (18).
Genetic susceptibility to RA is associated with the presence
of certain subsets of HLA class II DR1 and DR4 (19) that are
believed to be involved in presenting T cell epitopes that are
associated with joint inflammation. The antibodies recognizing
the citrulline-containing epitopes are predominantly of the IgG
class, and are of relative high affinity, suggesting an HLA class
II–restricted T cell response to the antigen presenting the cit-
rullinated epitopes. Therefore, the identification of an antigen
that bears citrulline-containing epitopes and is able to induce
an RA-specific HLA class II–restricted T cell proliferation
could be highly relevant to the disease processes in RA.
Our study provides further evidence that the antigen recog-
nized in the APF and AKA IIF test is indeed (pro)filaggrin.
The origin of the (pro)filaggrin-reactive autoantibodies and
their role in the pathology of RA is, however, not clear. Profil-
aggrin is expressed at a late stage during the differentiation
pathway of epidermal cells, and the presence of mature and
modified filaggrin is limited to the cornified cell layer of the
epidermis. It is therefore hard to imagine how filaggrin could
be presented to the immune system. Filaggrin has never been
detected in cells other than those encountered in squamous
epithelia, and its presence in synovial cells, for example, is un-
likely. Therefore, we postulate that the antibodies reactive to-
wards the citrullinated epitopes originate from a response
against a yet unidentified, cross-reactive protein (or proteins).
Such a protein should contain deiminated arginine residues
and some sequence resemblance to the peptides described
here.
In general, short synthetic peptides do not have a preferen-
tial conformation in solution, but can sometimes adopt moder-
ately stabilized secondary structures (20). Known structures of
antibody–peptide complexes show that peptides often adopt a
b-turn structure within the complex (21), and such b-turn mo-
tifs are frequently encountered within the filaggrin sequence
(22). In this scenario the role of filaggrin, due to its special
properties, is that of natural library of citrulline-containing
Table IV. Relation Between Anticitrullinated Peptide 
Antibodies (ELISA), APF, and RF in RA
Serum characterization
No. of positive sera (%)ELISA APF RF
1 1 1 79 (59)
1 1 2 8 (6.0)
1 2 1 8 (6.0)
1 2 2 7 (5.2)
2 1 1 12 (9.0)
2 1 2 0 (0)
2 2 1 12 (9.0)
2 2 2 8 (6.0)
*Sera reactive with at least one of the peptides cfc1-cfc9.
Table V. Reactivity of RA Sera Not Reactive on cfc1-cfc9, with 
Peptides from Other Profilaggrin Regions
Peptide* Positive sera‡
f12-31§ 0
cf18-31 3
cf18-34-1 1
cf18-34-2 0
cf18-34-3 2
cf48-65-1 0
cf48-65-2 0
cf48-65-3 0
cf48-65-4 8
cf260-276-1 0
cf260-276-2 0
*Peptide sequences can be found in Table I. ‡A subset of sera (n 5 32)
is used that were negative on cfc1-cfc9. §A negative control peptide that
does not contain a citrulline (Table I).
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epitopes presented in the right conformational environment.
Its sequence heterogeneity, the presence of deiminated argi-
nine residues, and the frequently encountered b-turn motifs in
the protein make filaggrin very suited for this role. 
Interesting sequence similarities have been encountered in
database searches using the sequence on which the cfc pep-
tides are based (Table I). For example, similarities with the
characteristic alternating arginine pattern were found in vari-
ous nucleic acid–binding proteins, some of which were of viral
origin (e.g., transcription-regulating proteins of human papil-
loma and herpes viruses). Papilloma viruses and the Epstein-
Barr virus (a gamma herpes virus) can infect epidermal cells,
in which the modifying enzyme peptidylarginine deiminase is
known to be expressed. 
Deimination of arginine residues has been described in de-
tail for two proteins: filaggrin and trichohyalin (22). The latter
protein is expressed in cells of the hair follicle and filiform
ridges of the tongue, and is reported to have a more globular
shape with many a-helical stretches (22). Antibodies reactive
to trichohyalin have not as of yet been identified in RA sera.
The enzyme that modifies arginine in a peptide context to
citrulline, peptidylarginine deiminase, is expressed in a broad
range of tissues and cell types (23, 24), suggesting that deimi-
nation of arginine within proteins is not a rare phenomenon.
The presence of this ubiquitous modifying enzyme in synovial
cells is therefore not unlikely, and its presence in hematopoi-
etic cell types known to infiltrate the synovium during joint in-
flammation has been shown (24). Little is known about the
function of the modification introduced by this enzyme. It was
suggested that deimination may play a role in the breakage
of inter- and intramolecular interactions, thereby making
proteins more susceptible to the activity of proteolytic en-
zymes (25).
The APF/AKA antibodies that are more specific for RA
compared with IgM RF are reported to be present in sera very
early in disease (8), even before other disease manifestations
can be observed (9). Moreover, the presence of the APF/AKA
antibodies are reported to be indicative for a more severe out-
come of disease (26). Unfortunately, the inconvenient test for-
mat (IIF) and inconvenient antigenic substrates used to deter-
mine the presence of the APF/AKA antibodies have hindered
their use as a serological marker. In the light of recent findings
that an early start of RA therapy with a combination of dis-
ease-modifying drugs is very successful in preventing disease
progression (27), a more convenient and reliable method of
determining the presence of AKA/APF antibodies would be a
valuable diagnostic tool. It is shown here that, in principle, the
early presence of APF/AKA antibodies, pointing very specifi-
cally to the development of RA, can be determined by ELISA
using synthetic peptides that contain citrulline. Our future ef-
forts will be directed to the identification of peptides with en-
hanced binding characteristics to the APF/AKA autoantibod-
ies. The identification of such peptides will not only enhance
their diagnostical usefulness, but will also provide more pre-
cise information on the nature of the antigenic determinants
responsible for the specific occurrence of APF/AKA antibod-
ies in RA sera.
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